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Background: Amikacin exhibits marked pharmacokinetic (PK) variability and is commonly used in
combination with other drugs in the treatment of neonatal sepsis. There is a paucity of amikacin PKKey words:
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sepsisx.doi.org/10.1016/j.curtheres.2017.01.001
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information in neonates from low-resource settings.
Objectives: To determine the PK parameters of amikacin, and explore the inﬂuence of selected covariates,
including coadministration with aminophylline, on amikacin disposition in neonates of African origin.
Methods: Neonates with suspected sepsis admitted to an intensive care unit in Accra, Ghana, and treated
with amikacin (15 mg/kg loading followed by 7.5 mg/kg every 12 hours), were recruited. Serum amikacin
concentration was measured at speciﬁed times after treatment initiation and analyzed using a
population PK modeling approach.
Results: A total of 419 serum concentrations were available for 247 neonates. Mean (SD) trough amikacin
concentration (from samples collected 30 minutes before the fourth dose) among term (n ¼ 25), and
preterm (o37 weeks’ gestation n ¼ 36) neonates were 6.2 (3.4) and 9.2 (5.7) mg/mL, respectively
(P ¼ 0.02). A 1-compartment model best ﬁtted amikacin disposition, and birth weight was the most
important predictor of amikacin clearance (CL) and distribution (V). The population CL and V of amikacin
were related as CL (L/h) ¼ 0.153 (birth weight/2.5)1.31, V (L) ¼ 2.94 (birth weight/2.5)1.18. There was a
high between-subject variability (58.9% and 50.7%) in CL and V, respectively. CL and V were 0.058 L/h/kg
and 1.15 L/kg, respectively, for a mean birth weight of 2.1 kg, and the mean half-life (based on
1-compartment model), was 13.7 hours.
Conclusions: The V and half-life of amikacin in this cohort varied from that reported in non-African
populations, and the high trough and low peak amikacin concentrations in both term and preterm
neonates suggest strategies to optimize amikacin dosing are required in this population.
& 2017. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Aminoglycosides in combination with other antibiotics such as
beta-lactams, are frequently used to extend the spectrum ofInc. This is an open access article u
sah, PhD, Department of
iversity of Ghana, Box LG 43,
nsah).antimicrobial activity for neonatal infection treatment.1 However,
near-ubiquitous resistance of common pathogenic organisms to
gentamicin has necessitated the increasing use of amikacin as
ﬁrst-line treatment.2 Amikacin exhibits wide interindividual vari-
ability in pharmacokinetic (PK) parameters during the neonatal
period3–6 and with unique PK characteristics among preterm
neonates. The wide interindividual variability in amikacin concen-
trations in heterogeneous neonatal populations require amikacin
therapeutic monitoring; however, such data rarely exist in mostnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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parameters in neonates of African origin, and there is no consensus
on target amikacin concentration ranges in different neonatal
populations. This makes it necessary to conduct setting-speciﬁc
studies to generate information that would improve understand-
ing of amikacin PK characteristics and optimize amikacin dosing in
such populations.
The PK characteristics of amikacin may be altered in conditions
such as sepsis7 and concurrent administration of amikacin with
nonsteroidal anti-inﬂammatory drugs during the ﬁrst day of life3
result in increased distribution volume (V) and reduced clearance
(CL), respectively. Other commonly used drugs in neonatal inten-
sive care settings may also alter aminoglycoside PK characteristics.
For example, methylxanthines increase urine output and ﬁltration
fraction.8 Aminophylline is used for management of apnea
of prematurity and is often concurrently administered with
amikacin in preterm neonates (o35 weeks’ gestation) with
suspected sepsis. However, the potential inﬂuence of coadminis-
tration of aminophylline on the CL of amikacin, which is excreted
largely via the renal route (but also with some amount of nonrenal
CL), is not known in this population. The aim of this study was to
describe the PK characteristics of amikacin in neonates with
suspected sepsis in a low-resource sub-Saharan Africa setting
where such information is unavailable, and explore the inﬂuence
of selected clinical and paraclinical parameters as covariates,
including aminophylline coadministration, on amikacin PK
parameters.Materials And Methods
Ethical issues
The Ethical and Protocol Review Committee of the University of
Ghana School of Medicine and Dentistry approved this study
(protocol ID: MS-Et/M.8-P.5.3/2011-2012). Written informed con-
sent was obtained from all parents and/or guardians of recruited
neonates.Study design and site
This was a prospective, nonrandomized single-site study con-
ducted at the neonatal intensive care unit (NICU) of the Depart-
ment of Child Health, Korle-Bu Teaching Hospital, Accra, Ghana,
from November 2013 to June 2014. The NICU is a tertiary referral
unit for neonates from health facilities in the southern regions of
Ghana. It is a 55-bed unit for preterm and sick neonates and is
located in close proximity to the obstetrics and labor wards of
Korle-Bu Teaching Hospital. There are about 2000 neonates
admitted to the NICU annually, of whom approximately 60% are
preterm births. Admission to the NICU is restricted to neonates
aged less than 48 hours unless in exceptional circumstances. The
unit changed the ﬁrst-line empirical treatment for neonatal sepsis
from gentamicin and ampicillin to amikacin and cloxacillin
because of increasing antimicrobial resistance of bloodstream
bacterial isolates in recent years.9Study population and inclusion criteria
Hospitalized neonates suspected of having sepsis, and in whom
a decision by the attending NICU physician to treat with amikacin,
with or without other therapy, were recruited. Neonates who were
known to have received any aminoglycoside before admission and
those with major congenital anomaly were excluded.Drug administration
Amikacin (Amikin®- Bristol-Myers Pharmaceuticals, Uxbridge,
England) 15 mg/kg body weight was administered as a loading
dose, followed by a maintenance dose of 7.5 mg/kg body weight
administered every 12 hours. Amikacin was administered in
combination with cloxacillin (50 mg/kg body weight every
12 hours) per the NICU dosing guideline at the time of this study.
Aminophylline 8 mg/kg body weight was administered as a
loading dose followed by a maintenance dose of 3 mg/kg body
weight administered every 8 to 12 hours to preterm neonates
(o35 weeks’ gestation) who required it for management of apnea.
The New Ballard Score (0.95 interrater reliability)10 was used to
determine gestational age. All needed drugs and supportive
therapy were given per standard NICU guidelines. Amikacin was
administered as an intravenous bolus over 2 to 3 minutes.
Blood sampling
Blood was collected via venipuncture from recruited neonates
by a study physician before drug administration for the laboratory
investigations described below. Blood samples were collected into
pediatric culture vials (BACTEC Peds plus/F, Becton-Dickinson,
Gauteng, South Africa) for culture and sensitivity, EDTA tubes for
full blood count, and serum separator tubes for C-reactive protein
(CRP) and procalcitonin (PCT) levels.
For amikacin levels, 1 or 2 blood samples (500 mL per sample)
were collected from each neonate into separator tubes,
centrifuged, and serum obtained immediately transferred into
Eppendorf tubes. Blood samples collected for the purpose of
determining peak amikacin levels were collected 1 hour after the
third dose, and samples for trough levels were collected
30 minutes before the fourth dose. Other samples (apart from
peak or trough) were collected after 2, 4, 6, or 8 hours (full PK
screen) following the third amikacin dose.
Laboratory analysis
Blood culture was done using the BACTEC 9240 blood cul-
ture system with subsequent biochemical species identiﬁcation.
Serum amikacin concentration was measured by particle-
enhanced turbidimetric immunoassay11 using an automated
method (Indiko; Thermo Fisher Scientiﬁc Inc, Waltham,
Massachusetts). The lower limit of quantiﬁcation of serum
amikacin concentration was 0.8 mg/mL and coefﬁcient of variation
was o6% over the entire calibration range (1.5–50 mg/mL). CRP
assay was performed with a BNII automated system (Dade-Behring
Inc, Newark, Delaware). An automated Elecsys (Roche Diagnostics,
Rotkreuz, Switzerland) was used to determine serum PCT. All
laboratory investigations were done free of charge for all recruited
neonates.
PK model building
PK parameters for the study population were estimated by a
nonlinear mixed-effects modeling approach using NONMEM
version 7.3 (ICON Development Solutions, Dublin, Ireland)
and Pirana version 2.8.2 (Pirana Software and Consulting BV).
R Software version 3.0.2 and R Package Xpose (R Foundation for
Statistical Computing, Vienna, Austria) were used for graphic
analysis of model outputs and exploratory covariate analysis.
First-order conditional estimation with interaction algorithm was
used throughout the model-building process.
The model-building process was done using concentration
versus time data after excluding data below the lower limit of
quantiﬁcation. One- and 2-compartment models with linear
Table I
Characteristics of neonates with data for pharmacokinetic modeling (N ¼ 247).
Parameter Median (range)
Gestational age (wk) 35 (25–44)
Birth weight (kg) 2.3 (0.9–5.2)
Postnatal age (h) 1.23 (0.16–21.75)
Apgar score (5 min) 7 (2–9)
Parameter n (%)
Preterm (o 37 wk gestation) 131 (53)
Coadministration with aminophylline 93 (38)
Presence of perinatal asphyxia* 52 (21)
Culture positivity† 13 (5)
Sex (M/F) 131/116
n Deﬁned as resuscitation at birth.
† Bacteria isolates include Streptococcus agalactiae (n ¼ 3), Klebsiella
pneumonia (n ¼ 2), Escherichia coli (n ¼ 1), Serratia odorifera (n ¼ 1), Coliform
bacillus (n ¼ 1), Pantoea sp (n ¼ 1), Staphylococcus aureus (n ¼ 1), Enterobacter
aerogenes (n ¼ 1), Streptococcus viridans (n ¼ 1), and Burkholderia cepacia
(n ¼ 1).
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NONMEM subroutines. The 1-compartment model subroutine
used was ADVAN1 TRANS2 parameterized as total drug CL and V.
The 2-compartment model subroutine used was ADVAN3 TRANS4,
parameterized as CL, central compartment volume of distribution
(V1), peripheral compartment volume of distribution (V2), and
intercompartmental CL. A statistical model was developed by
assessing between-subject variability (BSV), which was modeled
exponentially assuming a log normal distribution. Additive, propor-
tional and combined error models were compared to assess
residual error. BSV within the population was assessed by
assuming that parameters had a mean of zero and a variance of
ω2. Residual error was also assumed to have a mean of zero and
variance of σ2.
The effect of the following covariates, birth weight,
gestational age, postnatal age, aminophylline coadministration,
gender, blood culture result, presence or otherwise of perinatal
asphyxia, and acute phase protein (PCT and CRP) levels on
individual PK parameters was assessed by examining
parameter-versus-covariate plots. All potential covariates and
noncorrelated potential covariates were tested in a linear and
power function relationship on the model. Covariates were
systematically incorporated into the structural model and
retained if they improved ﬁt (backward elimination and forward
inclusion).
Initial estimates for variance (ω2) on BSV (η), and variance (σ2)
on residual errors (ε) corresponded to a coefﬁcient of variation of
50%. The main criteria for model comparison were as follows: the
likelihood ratio test, represented in NONMEM as a difference in
objective function of 3.84, which corresponds to a signiﬁcance
level of o 0.05, decrease in the variance of random effects,
goodness of ﬁt plots, and eta-shrinkage.12Table II
Categorization of serum amikacin level in term and preterm neonates after third amika
Neonate Peak (n ¼ 21)
435 mg/mL 20–35m g/mL o
Term 3/21 (14.3%) 7/21 (33.3%) 11
Peak (n ¼ 28)
Preterm 6/28 (21.4%) 10/28 (35.7%) 12
Comparison of proportions 0.2 0.7 0.
†P value based on χ2 test.
n Classiﬁcation as reported by Sherwin et al.4Model evaluation
The ﬁnal model was evaluated using goodness of ﬁt plots
of observed (DV) versus population-predicted (PRED) and
individual-predicted (IPRED) amikacin concentrations. Further
evaluation involved use of conditional weighted residuals
(CWRES) versus PRED. A bootstrap procedure (n ¼ 1000)13 was
used to assess the robustness of the ﬁnal model.Results
Characteristics of patients
There were 247 neonates of mean (SD) gestational age 35.2
(4.6) weeks, birth weight 2.5 (1.0) kg, and postnatal age 2.01 (2.7)
hours, admitted within 24 hours of delivery and whose data (419
concentration time points) were available for inclusion in the PK
analysis. Concentrations below the lower limit of quantiﬁcation
(4 time points) were excluded. The treatment period for
the recruited neonates ranged from 2 to 7 days. Overall mortality
was 8.1%. A summary of patient characteristics is shown in
Table I.
Peak and trough amikacin concentration proﬁles in term versus
preterm neonates
The peak amikacin concentration was not statistically different,
(P ¼ 0.5) between term [17.5 (9.3) mg/mL, n ¼ 21] and preterm
neonates [19.9 (10.5) mg/mL, n ¼ 28]. However, trough amikacin
concentration was statistically different between term neonates
(n ¼ 25) of mean (SD) gestational age 38.3 (0.9) weeks, and
preterm neonates (n ¼ 36) of mean (SD) gestational age of 33.2
(2.5) weeks (6.2 [3.4) vs 9.2 [5.7] mg/mL; P ¼ 0.02). The trough
amikacin serum concentration of 80% of term neonates, and 86.1%
of preterm neonates were higher than 5 mg/mL. In addition, the
peak serum concentration of 52.4% of term neonates, and 42.9% of
preterm neonates were lower than 20 mg/mL. Proportion of neo-
nates, term and preterm, with peak and trough levels below,
within, and above optimal amikacin ranges4 is shown in Table II.
Model-building process
The results of PK model development procedure are shown in
Table III. The data were best described by a 1-compartment model.
PK parameter versus covariate plot showed that birth weight
would explain some of the variability in CL and V (Figure 1) and
that a power, rather than a linear function of birth weight,
correlates better with CL and V. Birth weight as a covariate in
the model signiﬁcantly improved its ﬁt (difference in objective
function o 3.84), and the effect of this covariate on CL and V also
showed low variance (ω2) on BSV (Table III). An evaluation of thecin dose.*
Trough (n ¼ 25)
20 mg/mL o5 mg/mL 5–10 mg/mL 410 mg/mL
/21 (52.4%) 5/25 (20%) 16/25 (64%) 4/25 (16%)
Trough (n ¼ 36)
/28 (42.9%) 5/36 (13.9%) 22/36 (61.1%) 9/36 (25%)
2 0.3 0.7 0.1
Table III
Population pharmacokinetic model development.
Model
No.
Model description Objective
function value
Reference
Model
Difference in objective
function value
Variance in between-subject variability (%)
(clearance, volume of distribution)
1 1-compartment (ETA on clearance,
volume of distribution)
2232.1 – – 96.5, 99.7
2 1-compartment, CLTV ¼ θ1 (BW/2.5)θ2 2094.4 1 –137.7 54.6, 92.9
3 1-compartment, CLTV ¼ θ1 (GA/35.3)θ2 2128.6 1 –103.5 64.7, 97
4 1-compartment, CLTV ¼ θ1 (APG5/7.2)θ2 2204.1 1 –27.9 88.6, 90
5 1-compartment, CLTV ¼ θ1: GRP 0 CLTV ¼ θ2: GRP1 2161.3 1 –70.8 74.6, 103.5
6 1-compartment, CLTV ¼ θ1: SEP 0 CLTV ¼ θ2: SEP 1 2230.8 1 –1.3 96.2, 99.2
7 1-compartment, CLTV ¼ θ1: ASP 0 CLTV ¼ θ2: ASP 1 2228.4 1 –3.7 94.3, 100.8
8 1-compartment, VTV ¼ θ1 (BW/2.5)θ2 2148.8 1 –83.3 71.8, 91.9
9 1-compartment, VTV ¼ θ1 (GA/35.3)θ2 2179.0 1 –53.1 101,59.6
10 1-compartment, VTV ¼ θ1 (APG5/7.2)θ2 2217.5 1 –14.6 98.4, 84.1
11 1-compartment, VTV ¼ θ1: GRP 0 VTV ¼ θ2: GRP 1 2196.9 1 –35.1 99.1, 81.8
12 1-compartment, VTV ¼ θ1: SEP 0 VTV ¼ θ2: SEP 1 2231.7 1 –0.4 96.5, 99.7
13 1-compartment, VTV ¼ θ1: ASP 0 VTV ¼ θ2: ASP 1 2229.9 1 –2.1 96.6, 99
14 1-compartment, CLTV ¼ θ1(BW/2.5)θ3, VTV ¼ θ2
(BW/2.5)θ4
2058.1 2 –36.3 59.5, 54.6
15 1-compartment, CLTV ¼ θ1 (BW/2.5)θ3, VTV ¼ θ2
(BW/2.5)θ4, þ Block (ηCL, ηv)
2044.4 14 –13.7 58.9, 50.7
θ1, θ2, θ3 & θ4 ¼ Model Parameter Thetas; APG5 ¼ Apgar score at 5 minutes; ASP 0 ¼ no asphyxia; ASP 1 ¼ asphyxia; BW ¼ birth weight; CLTV ¼ Population CL;
ETA ¼ variance on between subject variability; GA ¼ gestational age; GRP 0 ¼ amikacin only; GRP 1 ¼ amikacin þ aminophylline; SEP 0 ¼ negative blood culture;
SEP 1 ¼ culture proven pathogenic bacteria; VTV ¼ Population V.
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gestational age, concurrent administration of amikacin with
aminophylline, Apgar score at 5 minutes, gender, results of blood
culture (positive or negative), PCT level, CRP level, and presence or
otherwise of clinically determined perinatal asphyxia did not
signiﬁcantly improve the model (Table III).
Model 14 compared with the base model (Model 1), showed
that the BSV on CL and V reduced by 37% and 45.1%, respectively.
Incorporation of a block structure on ω2 on BSV of CL and V to
explain the correlation between these 2 parameters, and the use of
proportional error showed a signiﬁcantly better ﬁt of the model
(Model 15).
Model evaluation
Goodness of ﬁt plots, DV versus PRED and IPRED, and CWRES
versus PRED, of the ﬁnal model are shown in Figure 2. Parameter
estimates for the ﬁnal model obtained after bootstrapping are
shown in Table IV. From the ﬁnal model, individual CL (CLi) and
V (Vi) are related by the equations:
CLi ¼ [θ1 (BW/2.5) θ3]  EXP (ηCLi);
Vi ¼ [θ2 (BW/2.5) θ4]  EXP (ηVi)
Shrinkage of this ﬁnal model was 14% for ηCL and 30% for ηV.0.6
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Figure 1. (A) Clearance derived from the base model versus birth weigThe mean half-life (pseudo SD) of amikacin based the on
1-compartment open model, obtained as ln(2) / CL/V, was 13.2
(2.2) hours.Discussion
The study was done to generate data on, and describe the PK of
amikacin in, a low-resource setting where amikacin is part of the
ﬁrst-line empirical treatment for suspected neonatal sepsis. The
design of the study, characteristics of the population, and ther-
apeutic practice of the setting also allowed an evaluation of the
effect of clinically important covariates, including coadministra-
tion of aminophylline, a drug that is used in preterm neonates in
study settings, on amikacin PK.
The data showed that the trough concentration of the majority
of neonates (80% term and 86.1% preterm) were higher than the
recommended 5 mg/mL, and peak concentrations (52.4% term and
42.9% preterm) were lower than the recommended 20 to 30 mg/mL
range suggested as optimal for multiple therapeutic regimens of
amikacin.4 A drug-monitoring study conducted in term and pre-
term Singaporean neonates reported relatively higher mean trough
serum concentrations: 9.97 (5.67) mg/mL and 14.4 (9.28) mg/mL,6
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Figure 2. (A) Observed data versus population and individual predictions from the ﬁnal model. (B) Conditional weighted residuals versus population predictions plot.
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nor trough level was reached in a majority of neonates. We were
unable to ﬁnd previous reports on amikacin PK from Ghana or a
similar sub-Saharan Africa setting in the published literature. The
data obtained from the present study therefore emphasize the
need for individualized monitoring of patients on amikacin ther-
apy. In particular, a higher dose (improved peak) and longer
intervals (lower trough) may be needed to optimize amikacin
dosing in study settings.4
The concentration-time data of amikacin among neonates in
the current study best ﬁt a 1-compartment model. This is con-
sistent with other studies that have reported a 1-compartment
model for amikacin disposition in neonates,3–5 but different from
others that reported a 2-compartment model for amikacin dispo-
sition among neonates.15 The differences in compartmentalization
between the present and other studies may be due to differences
in sample schedules or postnatal age differences. Additionally, data
from this study showed shrinkage of 14% for ηCL and 30% for ηV,
which is most likely due to the sparse sampling technique. It has
been reported that when shrinkage is higher than 20%, the
diagnostic plots based on individual predictions or residuals could
be misleading.16
From the ﬁnal model obtained in this study, amikacin CL of a
population with mean birth weight of 2.1 kg will be 0.058 L/h/kg,
which is comparable with the reported CL for a population with a
similar body weight proﬁle reported elsewhere (0.048 L/h/kg).5
Similarly, amikacin CL of a population with a mean birth weight of
1.38 kg will be 0.85 mL/min/kg, and this is comparable to the CL in
the report by Kenyon et al17 (0.84 mL/min/kg) for a population
with a mean body weight of 1.38 kg.
The data from the present study showed birth weight to be the
most important determinant of amikacin CL. Aminoglycoside CL
correlates well with glomerular ﬁltration rate,18 whereas body sizeTable IV
Estimates of ﬁnal population pharmacokinetic model.
Parameter Unit Estimate
Population clearance L/h 0.153
Population volume L 2.94
Power function on weight with clearance 1.31
Power function on weight with volume 1.18
Between-subject variability
Clearance % 58.9
Volume of distribution % 50.7
Residual variability
Proportional % 46.1(related to weight) and renal maturation (related to gestational
age) also correlate with glomerular ﬁltration rate.19 Introducing
birth weight as an explanatory covariate reduced BSV of amikacin
CL, and explained approximately 42% of the observed variability.
Although unexplained variability could be due to differences in
disease state and associated comorbidities (eg, birth asphyxia),
these factors did not appear to have an inﬂuence on the model
when introduced as covariates in this study. Although some
studies have reported that gender, postnatal age, and gestational
age (reported as postconception age or postmenstrual age in other
studies) may inﬂuence amikacin CL in neonates,4–6 these cova-
riates did not appear to inﬂuence CL in the current study.
Furthermore, the inclusion of only participants in the ﬁrst
24 hours of life precludes conclusions being drawn about the
effect of postnatal age.
Birth weight was also found to be the only determinant of
amikacin V in the current study. This is to be expected because
aminoglycosides (being hydrophilic compounds) will generally
exhibit a relatively larger V in neonates than in adults,20 partly
because of the higher percentage of total body water in neonates.
Because aminoglycosides are distributed in extracellular ﬂuid
(which positively correlates with total body water), and total body
water correlates positively with body weight, the determining
effect of birth weight on amikacin distribution found in this study
is consistent with these considerations. An effect of gestational age
would have been expected because preterm infants have higher
percent total body water than term infants, but the lack of
improvement of the ﬁt could also be ascribed to the close
association between birth weight and gestational age.
The data from the present study suggest that the V of a
population of average birth weight of 2.1 kg will equate to
1.15 L/kg. This is relatively large compared with 0.434 L/kg
reported by Botha et al5 with the same average body weight. ThisRelative standard error (%) After bootstrap (mean [95% CI])
4 0.153 (0.139–0.167)
9 2.97 (2.5–3.47)
8 1.32 (1.11–1.55)
16 1.18 (0.737–1.53)
7 58.0 (47.8–67.9)
28 50.8 (31.0–84.2)
4.5 46.1 (41.4–51.0)
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drug treatment, with a mean postnatal age of 2.01 hours in this
study versus 3.1 days in the study by Botha et al.5 This ﬁnding is
also consistent with the possibility of a decrease in V with
increasing postnatal age related to the progressive decrease in
extracellular ﬂuid volume (postnatal weight loss) within the ﬁrst
few days of life.21
The V of neonates obtained from the ﬁnal model of this study
was large (1.14 L/kg) compared with a study with comparable
average weight.22 However, the difference could be ascribed to
differences in postnatal ages between the 2 studies. Furthermore,
the half-life obtained for neonates in the present study for a 2.1 kg
mean body weight population, 13.7 hours, was longer than the
6.4 hours reported by Botha et al.5 The longer calculated half-life
obtained in this study could be a consequence of the large V of
amikacin obtained in this population.
Data from this study showed no overall signiﬁcant effect of
coadministration of aminophylline on amikacin PK characteristics.
However, neonates who received aminophylline tended toward
lower birth weights (and younger gestational ages), and this fact
could partly explain the lack of effect, because birth weight
explained some variability in amikacin CL and distribution.
Sepsis is characterized by vasodilatation and increased vascular
permeability.23 The resulting increase in permeability is respon-
sible for a ﬂuid shift,24 and may be consistent with a high drug V.
Introduction of the covariate positive blood culture (13 out of 247
patients) into the model did not have an inﬂuence on the V of
amikacin. The lack of effect may be due to variable sensitivity of
blood cultures in neonates with sepsis.25Conclusions
The ﬁndings from this study showed low peak and high trough
amikacin concentrations among neonates compared with those
from other settings. The calculated half-life and V of neonates also
differed from those reported in other studies (non-African pop-
ulation). Introduction of aminophylline coadministration as a
covariate had no inﬂuence on amikacin PK characteristics. These
ﬁndings suggest that a higher dose and extended interval, would
be required to optimize amikacin dosing in this population. Addi-
tionally, dosing in infants should incorporate allometric or age-
maturational rather than linear functions.Acknowledgments
This work was supported by the Health Platform of Building
Stronger Universities (BSU) in Developing Countries Initiative, a
Danish International Development Agency (DANIDA) funded collab-
oration between Danish Universities and University of Ghana. Seth
K. Amponsah, George O. Adjei, Christabel Enweronu-Laryea, Kwasi
A. Bugyei and Jorgen A. Kurtzhals designed the study. The clinical
work was coordinated by Seth K. Amponsah, under the supervision
of Christabel Enweronu-Laryea and George O. Adjei. The Laboratory
work was coordinated by Seth K. Amponsah, under the supervision
of George O. Adjei, Jorgen A. Kurtzhals, and Kwasi A. Bugyei. The
PK analyses were performed by Seth K. Amponsah and Kosta
Hadji-Popovski, under the supervision of Kim Kristensen and
George O. Adjei. All authors contributed to the writing of the
manuscript and approved the ﬁnal version.
The authors thank Dr. P. Amartey, Dr. B. Antwi,
Dr. D. Amewornu, Dr. K. Aduful, P. Pappoe, and A. Buabeng for
assisting in patient recruitment and data collection, and J. Tsakpo,B.A. Westh, A.M. Sulley, and M.K. Bjornsdottir who also assisted in
laboratory analyses of samples. The authors also thank the medical
and nursing staff of the neonatal intensive care unit of Korle-Bu
Teaching Hospital.Conﬂicts of Interest
The authors have indicated that they have no conﬂicts of
interest regarding the content of this article.References
[1] Yurdakok M. Antibiotic use in neonatal sepsis. Turk J Pediatr. 1998;40(1):
17–33.
[2] Houghton JL, Green KD, Chen W, et al. The future of aminoglycosides: The end
or renaissance? Chembiochem. 2010;11(7):880–902.
[3] Allegaert K, Anderson BJ, Cossey V, et al. Limited predictability of amikacin
clearance in extreme premature neonates at birth. Br J Clin Pharmacol. 2006;
61(1):39–48.
[4] Sherwin CMT, Svahn S, Van der Linden A, et al. Individualized dosing of
amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J
Clin Pharmacol. 2009;65(7):705–13.
[5] Botha JH, du Preez MJ, Miller R, Adhikari M. Determination of population
pharmacokinetic parameters for amikacin in neonates using mixed-effect
models. Eur J Clin Pharmacol. 1998;53(5):337–41.
[6] Treluyer JM, Merle Y, Tonnelier S, Rey E, Pons G. Nonparametric population
pharmacokinetic analysis of amikacin in neonates, infants and children.
Antimicrob Agents Chemother. 2002;46(5):1381–7.
[7] Rea RS, Capitano B, Beis R, Bigos KL, Smith R, Lee H. Suboptimal aminoglyco-
side dosing in critically ill patients. Ther Drug Monit. 2008;30(6):674–81.
[8] Osswald H, Schnermann J. Methylxanthines and the kidney. Handb Exp
Pharmacol. 2011;200:391–412.
[9] Enweronu-Laryea CC, Newman MJ. Changing pattern of bacterial isolates and
antimicrobial susceptibility in neonatal infections in Korle-Bu Teaching
Hospital, Ghana. East Afr Med J. 2007;84(3):136–40.
[10] Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard
Score, expanded to include extremely premature infants. J Pediatr. 1991;119(3):
417–23.
[11] Newman DJ, Henneberry H, Price CP. Particle enhanced light scattering
immunoassay. Ann Clin Biochem. 1992;29(Part 1):22–42.
[12] Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates
for diagnostics: problems and solutions. AAPS J. 2009;11(3):558–69.
[13] Bauer RJ. NONMEM Users Guide. Introduction to NONMEM 7.3.0. Icon Develop-
ment Solutions, Hanover, MD. 2014.
[14] Khan D, Khan F. Therapeutic drug monitoring of amikacin in preterm and term
infants. Singapore Med J. 2009;50(5):486–9.
[15] Smits A, De Cock RFW, Allegaert K, et al. Prospective evaluation
of a model-based dosing regimen for amikacin in preterm and term
neonates in clinical practice. Antimicrob Agents Chemother. 2015;59(10):
6344–51.
[16] Mould D, Upton R. Basic concepts in population modeling, simulation, and
model-based drug development—part 2: introduction to pharmacokinetic
modeling methods. CPT: Pharmacometrics Syst Pharmacol. 2013;2:e38.
[17] Kenyon CF, Knoppert DC, Lee SK, et al. Amikacin pharmacokinetics and
suggested dosage modiﬁcations for the preterm infant. Antimicrob Agents
Chemother. 1990;34(2):265–8.
[18] Koren G, James A, Perlman M. A simple method for the estimation
of glomerular ﬁltration rate by gentamicin pharmacokinetics during
routine drug monitoring in the newborn. Clin Pharmacol Ther. 1985;38(6):
680–5.
[19] Weber W, Kewitz G, Rost KL, et al. Population kinetics of gentamicin in
neonates. Eur J Clin Pharmacol. 1993;44:S23–5.
[20] Warner A. Drug use in the neonate: interrelationships of pharmacokinetics,
toxicity, and biochemical maturity. Clin Chem. 1986;32:721–7.
[21] Bauer K, Versmold H. Postnatal weight loss in preterm neonates less than
1500 g is due to isotonic dehydration of the extracellular volume. Acta Paediatr
Scand. 1989;360:37–42.
[22] Sardemann H, Colding H, Hendel J, et al. Kinetics and dose calculations of
amikacin in the newborn. Clin Pharmacol Ther. 1976;20(1):59–66.
[23] Hosein S, Udy AA, Lipman J. Physiological changes in the critically ill patient
with sepsis. Curr Pharm Biotechnol. 2011;12(12):1991–5.
[24] Gosling P, Sanghera K, Dickson G. Generalized vascular permeability and
pulmonary function in patients following serious trauma. J Trauma.
1994;36:477–81.
[25] Brown DR, Kutler D, Rai B, Chan T, Cohen M. Bacterial concentration and blood
volume required for a positive blood culture. J Perinatol. 1995;15(2):157–9.
